Bicara Therapeutics (BCAX) Competitors $11.04 +0.34 (+3.18%) As of 01:41 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCAX vs. MLYS, IBRX, CPRX, ALVO, OCUL, BLTE, IDYA, AGIO, ANIP, and RXRXShould you be buying Bicara Therapeutics stock or one of its competitors? The main competitors of Bicara Therapeutics include Mineralys Therapeutics (MLYS), ImmunityBio (IBRX), Catalyst Pharmaceuticals (CPRX), Alvotech (ALVO), Ocular Therapeutix (OCUL), Belite Bio (BLTE), IDEAYA Biosciences (IDYA), Agios Pharmaceuticals (AGIO), ANI Pharmaceuticals (ANIP), and Recursion Pharmaceuticals (RXRX). These companies are all part of the "pharmaceutical products" industry. Bicara Therapeutics vs. Its Competitors Mineralys Therapeutics ImmunityBio Catalyst Pharmaceuticals Alvotech Ocular Therapeutix Belite Bio IDEAYA Biosciences Agios Pharmaceuticals ANI Pharmaceuticals Recursion Pharmaceuticals Bicara Therapeutics (NASDAQ:BCAX) and Mineralys Therapeutics (NASDAQ:MLYS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk. Is BCAX or MLYS more profitable? Bicara Therapeutics' return on equity of -21.67% beat Mineralys Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Bicara TherapeuticsN/A -21.67% -20.89% Mineralys Therapeutics N/A -70.44%-65.51% Does the media favor BCAX or MLYS? In the previous week, Mineralys Therapeutics had 2 more articles in the media than Bicara Therapeutics. MarketBeat recorded 6 mentions for Mineralys Therapeutics and 4 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 1.31 beat Mineralys Therapeutics' score of 1.23 indicating that Bicara Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicara Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mineralys Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend BCAX or MLYS? Bicara Therapeutics presently has a consensus target price of $32.25, suggesting a potential upside of 192.13%. Mineralys Therapeutics has a consensus target price of $43.50, suggesting a potential upside of 9.90%. Given Bicara Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Bicara Therapeutics is more favorable than Mineralys Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bicara Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00Mineralys Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Which has higher valuation and earnings, BCAX or MLYS? Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBicara TherapeuticsN/AN/A-$68M-$3.17-3.48Mineralys TherapeuticsN/AN/A-$177.81M-$3.56-11.12 Do insiders and institutionals hold more shares of BCAX or MLYS? 84.5% of Mineralys Therapeutics shares are held by institutional investors. 15.5% of Bicara Therapeutics shares are held by insiders. Comparatively, 25.6% of Mineralys Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryBicara Therapeutics beats Mineralys Therapeutics on 10 of the 13 factors compared between the two stocks. Get Bicara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCAX vs. The Competition Export to ExcelMetricBicara TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$603.00M$3.09B$5.66B$10.35BDividend YieldN/A2.39%5.75%4.64%P/E Ratio-3.4921.1576.4226.06Price / SalesN/A448.06559.35125.80Price / CashN/A45.2537.6061.24Price / Book1.229.6412.366.33Net Income-$68M-$52.93M$3.29B$270.94M7 Day Performance5.75%2.58%0.89%0.06%1 Month Performance-8.31%6.33%3.37%6.02%1 Year Performance-57.04%19.25%60.58%28.09% Bicara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCAXBicara Therapeutics2.1293 of 5 stars$11.04+3.2%$32.25+192.1%-59.3%$603.00MN/A-3.4932Positive NewsMLYSMineralys Therapeutics2.5451 of 5 stars$36.21-2.4%$43.50+20.1%+224.4%$2.46BN/A-10.1728Positive NewsIBRXImmunityBio2.3446 of 5 stars$2.74+5.4%$10.75+292.3%-30.9%$2.46B$14.74M-5.71590High Trading VolumeCPRXCatalyst Pharmaceuticals4.9294 of 5 stars$19.76-1.1%$33.20+68.0%-4.4%$2.44B$491.73M11.9880Positive NewsALVOAlvotech3.3173 of 5 stars$8.12+1.1%$14.00+72.4%-27.6%$2.42B$491.98M35.301,032Analyst UpgradeOCULOcular Therapeutix3.784 of 5 stars$12.54-2.1%$17.83+42.2%+38.5%$2.23B$63.72M-9.80230Positive NewsGap UpBLTEBelite Bio2.8252 of 5 stars$66.80-3.9%$96.00+43.7%+50.7%$2.21BN/A-43.1010High Trading VolumeIDYAIDEAYA Biosciences3.9869 of 5 stars$24.53-0.3%$42.85+74.7%-15.4%$2.16B$7M-6.4780AGIOAgios Pharmaceuticals4.2671 of 5 stars$36.30-1.3%$56.00+54.3%-25.3%$2.14B$36.50M3.30390Positive NewsANIPANI Pharmaceuticals4.0502 of 5 stars$98.81+1.1%$88.25-10.7%+63.0%$2.12B$614.38M-128.32600Analyst ForecastRXRXRecursion Pharmaceuticals2.2268 of 5 stars$4.77-1.2%$7.25+52.0%-32.8%$2.10B$58.84M-2.68400Gap Up Related Companies and Tools Related Companies MLYS Competitors IBRX Competitors CPRX Competitors ALVO Competitors OCUL Competitors BLTE Competitors IDYA Competitors AGIO Competitors ANIP Competitors RXRX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCAX) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredIf you own dollars, read this...Former Goldman Exec: "A Strange Day Is Coming to America" Dr. David Eifrig, who warned of inflation months ...Stansberry Research | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicara Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
